Perseus Proteomics Sets FY2026 Forecast, Stays in Red as Licensing Push Continues

Perseus Proteomics, Inc. ( (JP:4882) ) has issued an announcement.

Perseus Proteomics Inc. has issued its previously undetermined full-year earnings forecast for the fiscal year ending March 31, 2026, projecting net sales of 135 million yen and a net loss of 758 million yen, or 50.88 yen per share. The guidance implies a modest increase in revenue and a narrower loss versus the prior year, reflecting ongoing R&D investment and controlled administrative costs despite the absence of new licensing deals.

Management said the forecast is based on the current status of out-licensing efforts for its key pipeline assets PPMX-T002 and PPMX-T003, which have yet to yield any agreements, leaving significant uncertainty around future revenue upside. Research and development expenses are expected to reach 604 million yen and total selling, general and administrative costs 892 million yen, underscoring the company’s continued bet on advancing these programs while it pursues licensing partners, a strategy that keeps it loss-making but preserves upside if deals are eventually secured.

The most recent analyst rating on (JP:4882) stock is a Hold with a Yen241.00 price target. To see the full list of analyst forecasts on Perseus Proteomics, Inc. stock, see the JP:4882 Stock Forecast page.

More about Perseus Proteomics, Inc.

Perseus Proteomics Inc. is a Japan-based biopharmaceutical company listed on the Tokyo Stock Exchange Growth market, focused on developing antibody-based pipeline products such as PPMX-T002 and PPMX-T003. The company’s business model emphasizes out-licensing these candidates to partners, positioning it as a research and development-driven player reliant on license income rather than large-scale in-house commercialization.

Average Trading Volume: 1,000,994

Technical Sentiment Signal: Sell

Current Market Cap: Yen4.11B

See more insights into 4882 stock on TipRanks’ Stock Analysis page.